AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 191 min read$HUMA

Jones Keith Anthony purchased $18K of HUMA

Jones Keith Anthony purchased 30,000 shares of Humacyte, Inc. (HUMA) at $0.59 on 2026-08-17.

Original reporting
SEC EDGAR · Jones Keith Anthony
Published Aug 19, 2026, 8:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 8:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$HUMA
Neutral
high confidence
Mentioned
$HUMA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HUMANeutralLow
01

Why it matters

The Form 4 filing provides the first public disclosure of insider buying, but the amount is trivial relative to market cap.

02

Market read

Limited relevance; the insider purchase is small and unlikely to affect stock price.

03

What to watch

Potential upcoming clinical trial data not disclosed; insider may be positioning ahead of news.

Relevance 4/10Novelty 4/10Timing: Filed Aug 19 2026 (same day)

Background

Humacyte is a clinical‑stage biotech developing tissue‑engineered vascular grafts.

Company-level read

Ticker impact

$HUMANeutralHigh confidence
Context

Director Jones Keith Anthony bought 30,000 shares for $17,820 in a Form 4 filing, indicating insider confidence.

Expected impact

Minimal short‑term impact; price likely unchanged.

Evidence & confidence

The transaction is under $20K and represents a 0.0% ownership stake, unlikely to move the market.

Market effects

Sector

No material effect on the biotech sector.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Insider purchase could be a routine portfolio rebalancing, not a bullish signal.

Key entities

  • Company
    Humacyte, Inc.

    Biotech firm developing vascular grafts.

  • Individual
    Jones Keith Anthony

    Director of Humacyte who made the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HUMA insider trading history →

Related articles

AUG 19
$HUMAMed

Humacyte (HUMA) Q2 2026 Earnings Call Transcript

Humacyte (HUMA) reported Q2 2026 product revenue of $0.4M, up from $0.1M, driven by Symvess launch. V012 Phase III trial met primary endpoint, showing 91 more catheter-free days for ATEV vs. AV fistula. Company targets Nov. 2026 sBLA filing for dialysis access, with potential 2027 launch. Cash position is $80.3M post-June equity offering. Net loss was $36.8M, with $54.4M loss for H1 2026. Management noted slower-than-expected trauma market adoption and reimbursement pressures.

fool.com3 min
AUG 19
$HUMAHighAI 9/10

Humacyte publishes Phase 3 trial results in Lancet journal

Humacyte Inc. (HUMA) published one-year Phase 3 trial results in The Lancet, showing its ATEV outperformed traditional methods for hemodialysis access in end-stage kidney disease patients. The study highlighted benefits for high-risk groups. The company plans to submit a supplemental BLA in 2H 2026 to expand Symvess's label.

investing.com2 min
AUG 19
$HUMAMedAI 8/10

A bioengineered vessel beat fistulas for women and men with obesity and diabetes on dialysis

Humacyte (HUMA) published one-year Phase 3 trial results in The Lancet Digital Health, showing its acellular tissue engineered vessel (ATEV) outperformed autogenous AV fistula in hemodialysis patients, especially women and men with obesity/diabetes. The company plans to submit an sBLA in H2 2026 for a second AV access indication. HUMA stock rose 21.20% on the news.

stocktitan.net2 min